Mylan rolling out $1B buyback after Perrigo failure; In first big fleet loss for Volkswagen, AZ cancels all its orders;

@FiercePharma: Indonesia's Kalbe and South Korea's Genexine link up for biomedical work. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: There are lots of changes going on among generics producers but here are the top players. Feature | Follow @EricPFierce

> In the wake of its failed hostile bid for Perrigo ($PRGO), Mylan ($MYL) has announced a $1 billion stock buyback plan. Report

> AstraZeneca ($AZN) has jettisoned Volkswagen Group from its corporate fleet, canceling all orders with VW, Audi, Seat and Skoda brands amid the ongoing emissions crisis. Report

> India needs a more predictable approach to intellectual property, a Novartis ($NVS) executive said there Tuesday, adding that investment there would be more sustainable with a more stable approach. Report

Medical Device News

@FierceMedDev: Crime syndicates are hacking devices to steal private medical information for profit. ICYMI last week | Follow @FierceMedDev

@EmilyWFierce: calling for more regulation of lab-developed tests prior to congressional hearing today. More from the WSJ | Follow @EmilyWFierce

> SI-Bone gets $39M+ in debt to market joint fusion implant system. Story

> FDA approves, Medtronic launches the first remote monitoring pacemaker app. Report

> Diagnostics companies jump into rapidly growing market for point-of-care superbug tests. Article

Biotech News

@FierceBiotech: ICYMI yesterday: J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex. Report | Follow @FierceBiotech

@JohnCFierce: Catalent stops production at French plant, brings in law enforcement after it twice detects tampering. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Fun reminder of pharma's insane margins: $NVS has a Map My Run ad for a multiple sclerosis drug. Item | Follow @DamianFierce

> Roche joins Novartis' billion-dollar bet on Ophthotech's eye drug. Report

> After Paris attacks, Isis Pharma finally mulls a name change. Story

> Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus. Article

Pharma Manufacturing News

> Top Novartis exec in India says two plants warned by FDA completing remediation. Item

> Baxter Singapore plant gets FDA OK to produce Advate hemophilia product. More

> Valeant adds recall to long list of problems. Article

> Regulator halts Catalent production at French plant where product sabotage suspected. Report

> Four Roche plants go up for sale in move to more high-potency, targeted drugs. Story

Drug Delivery News

> NC State team: Gold nanoparticles can control the shape of DNA, RNA. Report

> Avedro bags $32M in financing to expand use of its drug delivering ophthalmology platform. More

> Egalet announces patent for its abuse-deterrence platform. Item

> Swiss scientists take a look inside 'cubosomes' for drug delivery potential. Story

> RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. Article

Pharma Asia News

> Lee's Pharma affiliate licenses Tragara's TG02 oncology treatment for much of Asia. Story

> Indian drugmakers eye Japanese market for acquisitions. Report

> India looks to push development of biotech startups. More

> HK-based Chi-Med takes another regulatory step to Nasdaq listing. Article

> Australia's Mesoblast formally lists on Nasdaq. Item

And Finally... Iceland is the biggest per capita consumer of antidepressants worldwide, and the U.S. doesn't even make the top 12. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.